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The 230-kDa bullous pemphigoid antigen is a hemi-
desmosomal protein of the cutaneous basement mem-
brane zone. The primary sequences deduced from full-
length human cDNAs predict that this molecule 
consists of a central rod region and flanking globular 
domains. To get insight into regulation of the 230-kDa 
bullous pemphigoid antigen gene (BPAG1), and to 
evaluate evolutionary conservation of the amino-ter-
minus of the protein, we screened a mouse genomic 
DNA library with a O.3-kb cDNA corresponding to the 
5' end of the human 230-kDa bullous pemphigoid an-
tigen cDNA. A positive clone was isolated, and South-
ern analysis of the clone with the O.3-kb cDNA allowed 
isolation of a 3.0-kb Hind III fragment containing the 
5' end of the coding sequence. Alignment of the se-
quences of this subclone and human BP AG 1 sequences 
revealed that this fragment contained 2466 bp of 5'-
flanking DNA, upstream from the ATG translation 
initiation site, and 258 bp of translatable sequences 
that encode a putative polypeptide of86 amino acids at 
B ullous pemphigoid (BP) is a cutaneous blistering ?is-ease characterized by the presence of circulatlllg Im-munoglobulin (Ig)G autoantibodies in the patients' sera [1 - 3]. Western blot analyses of BP patients' sera have recognized at least two distinct proteins, bullous 
pemphigoid antigens (BPAs), that serve as autoantigens in this dis-
ease. The major antigen recognized by most patients' sera is a 230-
kDa protein, whereas another protein recognized by relatively few 
patients' sera has a molecular weight of 180 kDa [4 -8]. Immuno-
electron microscopic studies have demonstrated that these autoantl-
gens are localized to the hemidesmosomes in the basal keratino-
cyte/cutaneous basement membrane interphase [9-11]. 
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the amino-terminus of the protein. This deduced poly-
peptide showed '91 % homology with the correspond-
ing human sequence. The TATAAA and CCAAT 
consensus sequences, as well as several putative cis-re-
gulatory elements, were identified in the 5'-flanking 
region of the mouse DNA. To test the functional pro-
moter activity of the 5'-flanking DNA, three mouse 
BP AG 1 promoter / CAT reporter gene constructs, with 
the promoter segments spanning from -1133, -525, 
and -213 to -1, were developed. Transient transfec-
tions of mouse transformed keratinocytes (Pam 212 
cells) with these constructs revealed clearly detectable 
CAT activities, indicating that the 5'-flanking region 
contains a functional promoter. Furthermore, these 
experiments suggested that the upstream sequences 
contain upregulatory elements, as well as elements that 
confer, at least in part, tissue specificity to the expres-
sion of the mouse 230-kDa BP A gene. Key words: base-
ment membrane zone/blistering skin diseases. ] Invest Der-
matoI103:651- 655, 1994 
A human cDNA clone corresponding to the 230-kDa BPA se-
quences was first isolated by Stanley et 01 [12], and cloning of a 
mouse cDNA was first reported by Amagai et 01 [13] . We have 
subsequently isolated a composite of cDNA clones that encode the 
entire human 230-kDa BPA [14-16]. These cDNAs were used for 
chromosomal mapping of the human 230-kDa BPA gene (BPAG 1) 
to chromosome 6 [14], and for examination of the expression of the 
gene in cultured cells [15]. 
Recent data by Liu et 01 [17] have implicated antibodies recogniz-
ing the 180-kD BPA in the pathogenesis of BP. However, the 
precise role of 230-kDa BPA autoantibodies in the pathogenesis of 
BP is currently unknown. The 230-kDa BPA has been suggested to 
interact with intracellular intermediate filaments [18,19), and the 
striking similarity of deduced peptide sequences between the 230-
kDa BPA and desmoplakin I suggests that these molecules may 
belong to the same family of cell adhesion junction plaque proteins 
[20). Thus, the 230-kDaBPA is thought to be involved, by a yet-un-
known mechanism, in stabilization of the cutaneous basement 
membrane zone. 
The BP antigens are expressed exclusively in the stratified squa-
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mous epithelia [2,21] . Thus, it is plausible that the BPAG1 pro-
moter plays a critical role in the regulation of tissue-specific expres-
sion of this gene. W e have recently cloned the entire human 
BPAG 1 gene, including up to - 3 kb of the 5' -flanking DNA 
[22,23]. To understand the molecular mechanisms underlying the 
regulation of BPAG 1 gene expression in further detail, we have 
ch aracterized the 5' -flanking region of the mouse gene and devel-
oped BPAGl promoter/reporter gene constructs. This study shows 
evidence for transcriptional regulation in the tissue-specific expres-
sion of this gene. 
MATERIALS AND METHODS 
Isolation and Characterization of Mouse 230-kDa BPA Genomic 
Clones A mouse fibroblast genomic library in AFIX phage vector (Strata-
gene) was screened with a 0.3-kb cDNA corresponding to the 5' end of 
human BPA cDNA sequences (nucleotide positions +1 to 250; see (16]) , 
synthesized by polymerase chain reaction (PCR) amplification. The ge-
nomic clones isolated here were purified, and the inserts were characterized 
by restriction enzyme digestions and Southern analysis with the 0.3-kb 
cDNA [24]. The restriction endonuclease digestion products were fraction-
ated by electrophoresis on 1 % agarose gels, and the sizes of the DNA frag-
ments were estimated by comparison with standard DNA markers. Appro-
priate DNA fra gments were isolated by gel electrophoresis and subcloned 
into the Bluescript vector (Stratagene) for sequencing [24]. Nucleotide se-
quencing was performed on both strands using the dideoxynucleotide chain 
termination method, utilizing universal and reverse primers or with syn-
thetic oligonucleotide primers [25]. The computer search for comparison 
with human 230-kDa BPA sequences and for consensus sequences, includ-
ing the putative signal peptide, was performed by Genetix (Hitachi) and by 
pc/Gene (IntelliGenetics) programs. 
Construction of Mouse 230-kDa BPA Promoter/Chloramphenicol 
Acetyl Transferase (CAT) Reporter Gene Plasmids One genomic 
clone was found to contain the 5'-flanking DNA sequences of the mouse 
DPAG1 gene (see Results). To develop DPAG1 promoter/reporter gene 
chimeric constucts; double-stranded genomic DNA fragments were gener-
ated by PCR amplification. The primers used for PCR contained an XI/oI site 
in the 5' oligomer and a Hind III site in the 3' oligomer, which enabled direct 
cloning of the PCR products into pBSOCAT, a promoterless construct con-
taining the entire CAT gene, small t intron, and the polyadenylation signal 
in plasmid Bluescript (pBSK) [26] . 
Transient Cell Transfections and CAT Assays The reporter gene/ 
CAT constructs, as well as pBSOCAT (a negative control), 20 Jig each per 
20 cm2 plate, were used in transient transfection of mouse transformed 
keratinocytes (Pam 212 cells) [27], mouse melanoma cells (B16 cel ls) [28], 
and mouse colon carcinoma cells (CT 26) [29] cultured in modified Eagle's 
medium (MEM) with 10% fetal calf serum (FCS), and of mouse fibroblasts 
(NIH 3T3 cells), obtained from the American Type Culture Collection 
(ATCC) cell repository, cultured in MEM with 10% calf serum. The endog-
enous expression of the 230-kDa BP antigen in these four mouse cell lines 
was examined both at the protein and the mRNA levels. For assay at the 
protein level, indirect immunofluorescence of cell cultures was performed 
with serum from a patient with bullous pemphigoid with autoantibodies 
recognizing the 230-kDa BP antigen epitopes only, as determined by West-
ern analysis. The secondary antibody was a tetramethylrhodamine mouse 
anti-human IgG. The immunofluorescence detection was performed with 
standard procedures. At the mRNA level, the BPAG1 gene expression was 
determined by reverse transcription (RT)-PCR. First, total RNA was iso-
lated from the cultured mouse cel ls, and the synthesis of first-strand cDNA 
was catalyzed by avian myeloblastosis virus reverse transcriptase using the 
downstream primer shown in the legend to Fig 4. Subsequently, a 324-bp 
segment extending from positions +1801 to +2124, as indicated previously 
[13], was amplified by the primer pair shown in Fig 4. The PCR amplifica-
tion products were examined on 1.2% agarose gel electrophoresis. 
The transfections were performed with Lipofectin (Stratagene). In all 
transfections, the constructs were co-transfected with a SV2-p-Gal con-
struct, which was used as an internal control of transfection efficiency [24]. 
Following a 24-h incubation, CAT activity as an indicator of the promoter 
activity was determined by incubation with [14Cjchloramphenicol, as previ-
ously described [26]. Beta-galactosidase activity was determined in the same 
samples, and the CAT activ ity values were corrected for p-galactosidase 
activity to allow direct comparison of the BPAGl promoter activity in 
different ce ll cultures transfected in parallel. 
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"AC:CTTGTCC TTTGTCTCCC' T("C'TC' ACACC C'.AAAG AM\Cr. C'I\Tr.Tr.TGAC AGr.C l\crTC"T 
TC CCTCAGflG CTG CCI\CTCT r.CCTGTCTCT TJ\(i(;AG(,TGT rrTr;Tc. c Tf:G GTTGTATCGT 
CCCTCGTC"AC ACCcCTACTG TCGTCGGTTC TTTTGGCAGG r. I\ GT~TTGCTGC 
TTCTCTTTIIC TCCTGCTCCT TCCTTGACTT Ci\C CCTCC1\T GTTCTCTCCA GTAC'ItTCCC 
~GGCTC I\TATCCCTTT 1\1'1'1'1'1'1'1'T/\ A'!'CACTI\I\TT AT'GTGI\GTI\T. TGTTCI\GGGT 
TCTTTCCT'TG GTTATA"""" CI\1'1\,.1'1'C1'1' CATr.Cflr;TGT TTI\I\GCCACT TC,TTACTTAG 
GTATCCGCTC TGACA,\TCTA C, ACAC GACCT AT('ATTTTGG GTCCCTT ACC ACTCCCTTTC 
C1'C AATC CC A ACCACII.AAAC II.CAGII.CACGC II.GTGTAr.CTG TGTCCTCA CT CTCTTAGACII. 
CCGACTTCAC TGTTGCCATG GACTAATC, AA TTAAA(;ATAA TATATTACAT TATGAATGCA 
AACCC AAGTC CACC(,TTTAT TACTr.r.CT(:C ATCCTTC~A,\AG TTACCATGTC 
TACATAII.GCA GCCTATGII.AC TA AAATGAAC TGTI\AATGCT TAG(;GTGCAG CCC TTACJ\GC 
TAGTTAAAAT GJ\AGCATTAA ~T TGA ATTAAA G ACACCA,\ GAA AAGII.TAGTTT 
TGGTCA CTAC I\GCAGTATCA GAATTTTAAT GTGCATCATA I\TCCACTTTG TATTGTTII.CA 
GACTGCAT .... C .... TATCAC .... AA AGA AGTTTAT TATCT .... GGCT TGTGTTACAG TGCAAGTCTII. 
CTGT .... AGCCC AGTACTTCGG AI\G CT AAACA AGGGGCAGGG CAAGTTGCAA TTCAGCCTGG 
ACTII.TAGAAA AGACTGTCTC ATACTTTAAA AAAAAII.CAAG GGAAGAAGTT GG.TGACTC~ 
AGTTCCAGAG GTTGAGGGAT GCTGTC('AGG GCTGGCGTCT TTGAAGACCT GTGTGCTTCA 
CCTTC(CTGG TAG.A.GGGCAG AAAGG AGACT GAACC(;/,GGT GGCCGGTGAG CAATCAGATC 
GGCACAGGAG ACAI\C.A.GATC CTCACTGA AA CAGGAGAGCC AAT(;CTTCA" 1'IfCCCACTGC 
~CAGGAACC AACCTGCCCC TTTGATACTG ACACTCATTT ATTCATGAGG GTTGAGCCTT 
ANrCA CGTCA 1t:(;ATCTTCC CGTGTCTCGG TATCCTGTAC TGGGGATTGT GTTTGC AGCA 
CATGCGCTTT TGACATACAT TG~ ACAGCACAeT AATGA AATAA AGCGGTTGAG 
ACT'T'CAAGAC TGGGGAGCCA GTCTATTCTG GGT1'AGCTTT ATTA CTTGAA CTTGGAAGTC 
,."TGTGTCJ\,TA GACAAGTTCT TCAGTGTTGA GGCCTC'AGTT TCTTCATCTG TIIACAGATGA 
GGTTTTGTGT GTGAAATGTT TCCTTTCCTG GTACACAGAA ATCGTATAAG TGCAAGGCGC 
AG CTGTTCCT GII.TT'l'TAAT!...Q!!£TCTTTT ACTTGGTAAA TGCTCTTTGA AAATTAAAAT 
GTWAACTC!\" GTTTGGCTTT GThGAATTCG AGGTAGGGAA GTATTTAGAT AAAAACCTTC 
ATTTTTCTTG ACACAAGTCT TTTGTGGGCA CACA CCAGGT ATT(;CII.AATT II.TAGCTATGT 
GGCTCGGAGT GTGTAGII.M-;A CAII.ACAGGG .... AGAATCAATG TTCTTGGGGC CTGTACTII.GT 
CTGTGTGAAG AAGAAGCAAG CCCAGACACA TTCACACTTA GTTACTGAGC CAATATTCTG 
CGTGGM:;TC'l' TTCCCtrTTTA G~C AGTAGTGGCT TACCAGAGAG AGTTTATCAC 
ACAAAGAAAA AGTAATTGAA CAT1'TTTCCA GTTAATTTAA TGCCGTGAAC .... ATGGAAG AG 
ATGGTCAAAT GGA AA CAGAT TTGGTTTCTC ATTAAATTTG TGTGCTTGCT TATTCATTAT 
TGACTTATTG ATTAGTCCAG CATTTTACCT TGTGTTAGGA AGCACGTGGG ATCT GCTTGC 
TGTCCAGCAT TTGTCCAGCT GTGTG ATCTC ACCTTTGTGT TTCTGGTTGG TGCTTGGTAT 
TGATAGCATT ACCTTCACTG GTGCTGCCCG GGCTCCTGTG TACCTGAGTT GTTT'1'TTAGy r¥~~~~~~~~ ~~~~~~~~~~~~ ;~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ 
GCAAGCAAA T GAATctCTGT AGGC'hGGATT CTTTAGIIATA GTTATCAGCA TAGTATTTGC 
AGTGCATTGC ATATCACGCC ACAGCt-li'ATT T ¥ CG ATCCG TTAAAGCCCT GCCCCTCCTT 
'M'AGACTGCC TTCACCTGGT A(;AAGTTCTC CTCGCATGGT CCTAGGACAG CA1"l'TCAGGA 
CCGA AAATCC AGACTAGTAG C'TACAGT'I"AC CGTACCAGTC ACTCTGTCTT TAGTMCACC 
AGCACTCGGA CTAGTCTGGA 'M"CCAATGAG AA1"CTCCTCT CCG"M'CA'M'G TGGTCCCACC 
CTCATCAACT CC'T"GCATTAG CT'I"CACTMT GAGTCCTTGG ATCCACACAG GTACGCAATC 
TTCACCATGA GGTTGTCTTT CC,.TCCTTAC AGGGGTCGTA TTTGCGGACT GGTTAC,CTCT 
TTGACTTCAA II.A'\{I.AAGAAG ATTTTT,.TT,. CT C,.TTTCCC TTTGACCCTT TTIIGC1'"I'GGA 
TATCCTCCAG CAGATTCCCA CCCCAC'M'CA GAGCGATAGT GTCAGCTGCG M GACAAA<:T 
CATCCTCGCC CGAAATCC-rC TCCAGTC'TGT AfI.(-;T(,GIICTT CAACC,GCTAG G(;CTTGCTGT 
AGAGGGCTGG TGTGTGCTCG G(;'1'AAI\CGGS AII.;\('TTCC AC ,\IICIIGTT(;AT TGACT('CT,\G 
GACCTGT'f('T CTGCII.GAA(;(' T'l' 
Figure 1. Nucleotide sequences of genomic DNA at the 5' end of the 
mouse 230-kDa bullous pemphigoid antigen gene (BPAG1). This 
Hi"d III fragment contains 2466 bp of 5'-flanking sequences, 237 bp of 
intron sequences, and 258 bp of coding sequences (bold) corresponding to 
exons 1 and 2. The sequences comprising the 5' -flanking region from -1 to 
- 2466 are numbered upstream from the ATG (+ 1 to + 3) translation initia-
tion site. Note the presence of a putative TATA box (brackets) and CCAAT 
box (dots abo/le) . The followin g putative cis-acting clements are identified: 
seven AP-1 binding sites (LJ) , four AP-2 sites (n), a cAMP-responsive 
clement (boxed) , and five glucocorticoid responsive clements (Imderli'lfd). 
Also, note the presence of two potential CK-8mer sites (double IltIderli"ed), 
which may confer keratinocyte-specific expression to the gene. The nucleo-
tide sequence has been deposited in the GenBank under accession nnmber 
U13641. 
RESULTS 
Isolation of Genomic DNA Containing the 5'-Flanking Re-
gion of the Mouse BPAGl Gene A 0 .3-kb 5' fragment of 
human 230-kDa BPA cDNA was used to screen a mouse genomic 
DNA library. A positive clone, about 15 kb in size, was isolated and 
characterized by multiple restriction endonuclease digestions, fol-
lowed by Southern hybridizations. Hybridization with the O.3-kb 
human cDNA allowed isolation of a 3.0-kb Hind III fragment. In 
Northern blot analysis with mouse keratinocyte RNA, this frag-
ment hybridized with a - 9-kb transcript, which corresponds to the 
size of mouse 230-kDa BPA mRNA [13] (data not shown) . This 
DNA fragment was subjected to nucleotide sequencing; the entire 
sequence of this fragment is shown in Fig 1. 
Comparison of Human and Mouse Sequences Comparison 
of the nucleotide sequences of the Hind III fragment with human 
230-kDa BPAG1 eDNA sequences revealed that this clone con-
sisted of sequences corresponding to the 5' end of the cDNA and of 
5' -flanking genomic sequences. Analysis of nucleotide sequences 
allowed us to deduce 86 amino acids at the most N-terminal end of 
the mouse 230-kDa BP A protein, corresponding to exons 1 and 2 
on the coding region (see Fig 1). Alignment of the deduced human 
[16] and mouse amino acid sequences showed a high degree of 
homology, with an extra threonine residue being present in the 
human sequence (Fig 2). The overall homology in this region was 
91 % at the amino acid level and 85% at the nucleotide level. To 
detect a putative eukaryotic secretory signal sequence [30], we ana-
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Figure 2. Comparison of deduced amino acid sequences at th.e 
amino-terminal end of mouse and human 230-kDa bullous pemphI-
goid antigens. The presence of the ~utat ive signal peptidase cleavage site, as 
predicted by computer analySIS, IS 1I1dlcated (solId tnallgle) . . However, ~s 
discussed in the text, this computer predIction may not 1I1dlcate bIOlogIc 
functionali ty. DOl/ble dots, identical amino acids; sillgle dots, conserved amino 
acids. Note the presence of an extra threonine residue (T) inserted mto 
position + 18 of the human sequence (solid circle) . T he overall homology of 
these sequences is 91 %. 
lyzed sequence 1-86 with a computer pro.gram. The prog.ram pre-
dicted that the mouse polypeptide conta1l1s a putative Signal se-
quence of 42 amino acids (Fig 2). 
Sequence Analysis of the S'-Flanking DNA The nucleotide 
sequence of the 2466-bp segl~ent u~s.tream from the translation 
initiation codon ATG (nucleotide position + 1 to + 3) revealed sev-
eral features suggestive of a promoter. Specifically, a canonical 
CCAAT motif was located in the position -[247 to 243) and a 
variant of the consensus TAT A(A/T)A sequence, T A TTT A, was 
identified in the position - [100 to 95). These sequences are well 
conserved between the mouse and human BPAGl 5'-flanking re-
gion, and specifically, the correspond~ng consensus sequences are 
present in the human gene in nucleotide pos~tlons - [283 to 2?9] 
and - [133 to 128), respectively (22). In addlt1o~ to these mot.lfs, 
e ight putative AP-l binding site~ (3.1), four putative AP-2 bmdmg 
sites (32), five putative glucocortiCOid responsive e l.eme~ts [3? ,34], 
and a putative cAMP responsive element l~5] were Identified m the 
mouse sequence (Fig 1). Also, two putative CK-8m~r sequences, 
AARCCAAA, which have been suggested to confer tissue-speCific 
expression on several genes in epidermal cells [36 - 38), wer~ identi-
fied in the positions - [ 11 84 to 1177] and - [?45 to 638] (Fig 1). A 
similar consensus sequence was also fou~d 111 the human BPAG 1 
promoter region [22], suggesting functional Importance. Dlre~t 
comparison of the mouse and human nucleotide sequences wlth111 
-1 to -500 indicated 63.4% identity. The above data suggested 
that - 2.5 kb of 5' -flanking DNA is representative of the promoter 
region of the mouse BPAG 1 gene. 
Expression of Mouse BPAG1 Promoter/CAT Reporter 
Gene Constructs in Cultured Cells To test the functIOna l pro-
moter activity of the 5' -flanking region, three chimeric promoter / 
CAT reporter gene plasmids were developed by inserting segments 
extending from -1 133 to -1 (construct pMBPCAT 1133), from 
-525 to -1 (construct pMBPCAT 525), and from - 213 to -1 
(construct pMBPCAT 213) into pBSOC AT, a promoterless vector 
[26]. These constructs were then tested in transient transfections of 
several mouse cell lines. All transfections were performed in parallel 
with pSV2CAT (a positive control) and with pBSOCAT (a nega-
tive control). 
The constructs pMBPCAT 1133, pMBPCAT 525, and 
pMBPCAT 213 were utilized in transient transfectlOns 111 c~ltures 
of Pam 212 keratinocyte, B16 melanoma, CT26 colon carCll1oma, 
and NIH3T3 fibroblast cell lines. To examine whether these cells 
express the BPAG1 gene, two types of ex~eriments were per-
formed . First, indirect immunofluorescence With serum from a pa-
tient with BP, which by Western blot analys is was shown to react 
only with the 230-kD BPA, was performed. Bright immunostain-
ing was noted on cultured Pam212 cells (Fig 3A). In contras t, t1~ree 
other mouse cell lines used in this study, B16 melanoma celllll1e, 
CT26 colon carcinoma cell line, and NIH 3T3 fibroblast line, gave 
MOUSE BPAG1 PROMOTER 653 
Figure 3. Indirect immunofluorescence. Mouse Pam 212 keratinocyte 
(A ), B16meianoma (B), CT26 co lon carcinoma (C), and NIH3T3 fibroblast 
(D) cclilines under indirect immunoflu orescence wi th a serum recognizing 
the 230-kD bullous pemphigoid antigen epitopes. Note bright immunoflu -
orescent staining on Pam 212 cells, w hereas the sta ining reaction in the three 
other cultures is essentially negative. 
an essentiall y negative stallung reac tion (Fig 3B-D). Secondly, 
RT-PCR of mRNA isolated from these four different cell lines was 
performed. Following reverse transcription, a segment correspond-
ing to nucleotides + 1801 to + 2124 was amplified by PCR using 
primers as described in Materia ls alld Methods. An amplification 
product of the expected size, 324 bp, was noted only w hen Pam 212 
cellmRNA was used as the template (Fig 4, laneA). In contrast, no 
band of similar size was obtained in mRNA products from the three 
other cell lines tested (Fig 4, lanes B - D). Thus, significant expres-
sion of the mouse BPAG 1 ge ne could be detected only in Pam 212 
cells, as determined at th e mRNA and protein levels. 
The same mouse cell lines tested above were then utilized in 
transient transfections with the PBAG 1 promoter/CAT constructs. 
Assay of CAT activi ty in the cells transfected with the pMBPCAT 
1133 construct revealed a strong signal in Pam 2 12 cells and a low 
level of expression in NIH3T3 cell s, w hereas essentially no activity 
was detected in B16 or CT26 cells (Fig SA). Quantitation of the 
ABC D M 
400bp 
/ 
~OObp 
Figure 4. RT-PCR analysis. BPAG1 mRNA in Pam 212 (Ialle A) , B16 
(Ialle B) , CT26 (ItlIle C), and NIH3T3 (Ialle D) ce lls was analyzed. Total 
RNA was isolated, and the first-strand cD N A was generated by reverse 
transcription, as described in Ma terials alld Methods. A 324-bp segment was 
then amplified by PCR using the foll owing primers: upstream primer, 5'-
GTCAITGACCCTGTGAGAGGC-3' (position + 1801 to + 1821); 
downstream primer,S' -AA T C AGGTTTCTCTGGAAAGC-3' (position 
+ 2124 to + 2104). A clearly detectable band of the expected size was noted 
only in lalle A, indicating that Pam 212 cells express the BPAG1 gene at the 
mRNA level. Lalle M contains molecular weight markers, with 300- and 
400-bp bands as indicated. 
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Figure 5. Assay of CAT activity. Cultures of different cell types were 
transfected with the pMBPCA T 1133 construct, which contains the seg-
ment from -1133 to -1 of the 5'-flanlcing DNA of the BPAG1 gene. 
Parallel transient transfections we.re made with the promoterless pBSOCA T 
construct as a negative control. A) Lane 1, Pam 212 cells transfected with 
pBSOCAT (negative control); lane 2, Pam 212 cells; lane 3, B16 melanoma 
cell s; lane 4, CT26 colon carcinoma cells, and lane 5, NIH3T3 cells, all 
transfected in parallel with the construct pMBPCAT 1133. B) Quantitation 
of CAT assays similar to those shown in (A). The relative values are ex-
pressed as radioactivity in the acetylated form of(14C) chloramphenicol. The 
values are mean ± SD of three separate experiments. 
relative actiVity by counting the radioactivity in the acetylated 
forms of(14C] chloramphenicol revealed that the level of expression 
in NIH3T3 cells was only about 30% of the level observed in Pam 
212 cells (Fig 5B). The level of expression in B16 and CT26 cells 
was the same as that observed in cells transfected in parallel with the 
promoterless pBSOCAT parent construct as a negative control (Fig 
5A.B) . 
To examine the relative activities of the three promoter/CAT 
constructs, extending from - 213, -525, and -1133 to -1, respec-
tively, they were used in similar transfections of Pam 212 cells. The 
CAT activity of the pMBCAT 1133 construct was essentially the 
same as that of pMBPCAT 525, whereas pMBPCAT 213 showed 
considerably lower activity than the other two constructs tested 
(Fig 6). 
DISCUSSION 
The screening of the mouse genomic DNA library with a human 
cDNA clone resulted in isolation of one positive, - 15 kb, lambda 
phage clone that was shown to correspond to the 5' -end of the gene 
and to contain upstream flanking sequences. Specifically, sequence 
analysis of a 3-kb Hind III subclone revealed sequences with a high 
degree of homology with those of human BP antigen cDNA, and 
Northern blot analysis with this genomic fragment recognized 
-9 kb mRNA, which corresponds to the size of the mouse 230-
kDa BP transcript [13]. These results indicated that we had isolated 
a genomic clone that contains sequences corresponding to the 
mouse 230-kDa BPAGI gene. 
We have recently elucidated the full-length primary sequence of 
the human 230-kDa BPAGI by cloning overlapping cDNAs [16]. 
Analysis of deduced amino acid sequences, using a computer pro-
gram, predicted a putative signal peptide of 43 amino acids and the 
presence of a membrane-associated sequence of 17 amino acids. The 
latter computer prediction was taken to suggest that the 230-kDa 
BPA may be a membrane-associated protein [16]. Search for a signal 
sequence in the mouse gene also identified a putative signal pepti-
dase cleavage site, a Ser-Cys bond at position 42-43. However, 
several lines of evidence, based on immunofluorescence and im-
munoelectron microscopic data, have strongly suggested that the 
230-kDa BP antigen is an intracellular protein [9,10,39,40]' Thus, 
the computer prediction of a signal peptide, suggesting secretion of 
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the protein, may not be indicative of biologic function. However, it 
remains to be seen whether the 230-kD BP antigen, which appar-
ently forms the intracellular hemidesmosomal plaque, is associated 
with the inner portion of the plasma membrane. 
We previously compared human amino acid sequences deduced 
from a 2.3-kb BPA cDNA at the carboxyl terminal portion of the 
protein [15] with corresponding mouse sequences [13]. The homol-
ogy in this area between mouse and human sequences was 83% at 
the amino acid level and 80% at the nucleotide level. In the present 
study we showed that the deduced 86 amino-acid segment at the 
N-terminus of the mouse polypeptide had 91 % homology with the 
corresponding human 230-kDa BP antigen sequence. These results 
indicate that both the N-terminus and C-terminus of the 230-kDa 
BP antigen appear to be well-conserved between mouse and human, 
suggesting functional importance for these segments of the protein. 
Sequence analysis of the 5' -flanking region of the mouse BPAG 1 
gene revealed the presence of several sequences that were homolo-
gous to the sequence elements thought to playa role in the regula-
tion of the human gene. To test the functional promoter activity of 
the 5' -flanking region of the mouse gene, we performed transient 
transfections with three constructs, pMBPCAT 1133, pMBPCAT 
525, and pMBPCAT 213, first in Pam 212 cell cultures. We were 
able to detect strong CAT activity with all three constructs, sug-
gesting that these fragments contained 230-kDa BPA promoter. 
Furthermore, these experiments revealed that the CAT activities 
with pMBPCAT 1133 and pMBPCAT 525 were clearly higher 
than that obtained with pMBPCA T 213. This finding suggests that 
the 312-bp segment between positions -525 and -213 contains 
some cis-elements that confer upregulation of the expression in 
keratinocytes. Careful examination of this upstream sequence iden-
tified a canonical CCAA T motif at - [247 to 243], which is possibly 
responsible for the difference in the CAT activities between the 
shortest and the two longer constructs. 
The 230-kDa BP antigen is expressed in the stratified squamous 
epithelia and possibly in a few other tissues [2,21 ]. Previous studies 
on the human BPAG 1 gene have indicated that the promoter region 
of the gene contains cis-regulatory elements that are responsible for 
tissue-specific expression of this gene. Within the 5'-flanking re-
gion of the BPAG 1 gene, we found sequences highly homologous 
>- 450 I- 400 
> 350 
I- 300 U 
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I.J..J 200 
> 150 
I- 100 
« SO 
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a::: 213 525 1133 
pMBPCAT pMBPCAT pMBPCAT 
Figure 6. Assay of CAT activity in Pam 212 cells transfected with 
mouse 230-kDa BPA promoter/ CAT constructs. The constructs 
pMBPCAT 213, pMBPCAT 525, and pMBPCAT 1133 contain segments 
from -[213 to 1], - [525 to 1], and -[1133 to 1], respectively, of the 5'-
flanlcing DNA. The CAT activities were determined as shown in Fig SA. 
The activity of the pMBPCAT 1133 construct was essentially the same as 
that of pMBPCAT 525, whereas pMBPCAT 213 showed significantly 
lower (p < 0.01) activity than the two larger constructs. The values are 
expressed as in Fig 5B, and are mean ± SD of three separate experiments. 
VOL. 103, NO.5 NOVEMBER 1994 
to CK-8mer and AP2 sequences, which have been suggested to be 
involved in tissue-specific expression of epidermal genes [36-43], 
These sequences are found both in human and mouse BPAGl pro-
moter regions, and a specific AP-2-like cis-element, KRE2, has 
been shown to contribute to the tissue-specific expression of the 
human BPAG1 gene in keratinocytes [22,23]. To examine the pos-
sibility that the mouse gene may display similar tissue specificity, 
transient transfections using Pam 212, NIH 3T3, B16, or CT26 
cells were performed with the construct pMBPCAT 1133. Indirect 
immunofluorescence analyses and RT-PCR amplification of 
BPAG1 mRNA sequences revealed that this gene was expressed at 
significant levels only in Pam 212 cells, whereas the B16, CT26, 
and NIH3T3 cells showed minimal expression. High levels of CAT 
activity were observed only in Pam cells (Fig 5). Significantly lower 
expression was detected in NIH3T3 cells, whereas B16 and CT26 
cells showed no activity, The reasons for the low, yet detectable, 
level of expression in NIH3T3 cells are not entirely clear, but these 
results may suggest that additional factors outside of the promoter 
region may be required for absolute tissue specificity, Such elements 
could reside in further upstream regions of the gene, within the first 
intron (as suggested, e.g. , in the case of type I collagen [44,45]) or in 
the 3/-end of the gene (as suggested in the case of keratin 1 [46]). 
Thus, the 1.1-kb segment of 5' -flanking sequences of the mouse 
BPAG 1 gene appears to contain cis-acting elements that confer, at 
least in part, tissue specificity to the expression of the BPAG 1 gene, 
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